Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV herbal pill trial pulled before a single patient enrolled

NCT ID NCT04770701

Disease control Sponsor: Trieu, Nguyen Thi, M.D. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test a blend of plant extracts and vitamin C, called Ahah, in people with HIV/AIDS. The goal was to see if it could protect and increase CD4+ T cells and B cells. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
herbal extract blend (Eclipta prostrata, Dioscorea cirrhosa, Phyllanthus urinaria, Adenosma glutinosum, Impatiens balsamina) plus vitamin C

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Started

Sep 2020

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection. Characterized by rapid loss of resistance: AIDS * Dermatitis, mouth ulcers, skin rash, itching, weight loss * HCV (+), HBV (+), Tuberculosis (+) Exclusion Criteria: * Cancer under all form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIDS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AIDS HIV-1-infection

Contacts and locations

Locations

  • Saigon Biopharma Company Limited

    Ho Chi Minh City, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.